EDO

PepGen Appoints Caroline Godfrey, Ph.D. to the Company’s Scientific Advisory Board

Retrieved on: 
Friday, July 22, 2022
EDO, University, GLOBE, University College London, SEC, Medical Research Council (United Kingdom), Research, Form 10-Q, Genetics, Private Securities Litigation Reform Act, Medical Research Council, Coronavirus Scientific Advisory Board (Turkey), Technology, Science, Neuromuscular Disorders, Patient, Therapy, Innovation, UK Research and Innovation, Neuromuscular disease, Peptide, Form, Pharmaceutical industry, Management, Fine chemical, Discovery

In connection with this appointment, Dr. Godfrey leaves her position as Senior Vice President of Discovery at PepGen.

Key Points: 
  • In connection with this appointment, Dr. Godfrey leaves her position as Senior Vice President of Discovery at PepGen.
  • Caroline is one of our scientific co-founders, and was appointed as the first Chief Executive Officer of PepGen following the companys spinout from the University of Oxford and the Medical Research Council of United Kingdom Research and Innovation.
  • We are incredibly grateful for all that Caroline has done for PepGen and look forward to her continued contributions.
  • Im excited to be moving into a new position on PepGens Scientific Advisory Board, said Dr. Godfrey.

PepGen Reports First Quarter 2022 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, June 16, 2022
FDA, Senior, Therapy, IPO, Safety, NHP, Achievement, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CEO, Research, Company, Health Canada, Private Securities Litigation Reform Act, Clinical trial, Peptide, EDO, GLOBE, IND, SEC, Research and development, Development, HNV, Home After Three Months Away, Adult, Food, Patient, Board, PGN, DMD, DM1, Duchenne muscular dystrophy, Administration, Form, Drug, Male, Form 10-Q, Pharmaceutical industry, Life insurance, Online gambling, Toxicology

BOSTON, June 16, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (PepGen), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the first quarter ended March 31, 2022.

Key Points: 
  • BOSTON, June 16, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (PepGen), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the first quarter ended March 31, 2022.
  • In May, PepGen completed an initial public offering, raising $122.9 million in gross proceeds before deducting underwriting discounts and offering expenses.
  • In March, PepGen received clearance from Health Canada of its Clinical Trial Application to initiate the Companys first-in-human trial of PGN-EDO51.
  • Financial Results for the Three Months Ended March 31, 2022
    Cash and cash equivalents were $118.9 million as of March 31, 2022, which excludes the proceeds from our IPO in May 2022.

EDO Appoints Raman Sehgal as Head of Marketing

Retrieved on: 
Wednesday, June 15, 2022
Advertising, Discovery, SoFi, Royal Caribbean, NBCUniversal, Convergence (TV program), Convergent, Technology, T-Mobile US, CEO, Patronage, Knowledge, Marketing, P&G, Leadership, Shamrock Holdings, TaylorMade, Growth, Consumer, Kia, EDO, Acceleration, Investment, Warner Bros., Fox, IBM, CBS, Univision, B2B, Danone, Awareness, VP, Amazon Studios, GLOBE, TracFone Wireless, Hyundai, Sales, Management, New Balance, Paramount, Nissan, Subway

Sehgal has over twenty years of experience leading marketing and media teams at multinational brands including P&G and Danone, along with other successful technology and data startups.

Key Points: 
  • Sehgal has over twenty years of experience leading marketing and media teams at multinational brands including P&G and Danone, along with other successful technology and data startups.
  • Previously, Sehgal served as VP of Marketing for TVision, where he was responsible for leading the marketing team in brand building and sales enablement.
  • In his role, Sehgal brought a digital approach to the TV measurement industry, a method he will continue at EDO.
  • His responsibilities will include raising the companys profile, leading marketing strategy, scaling brand awareness, thought leadership, product marketing and sales acceleration for EDO.

Cosmetic Executive Women (CEW) Hosts Annual Women's Leadership Awards

Retrieved on: 
Tuesday, June 7, 2022
Linda, Online, Cosmetic Executive Women, Ulta Beauty, Multimedia, Thought, Ghana UK-Based Achievement Awards, View, Global Leadership Awards, Workplace, East, Knowledge, Partnership, Cosmetic, Clarins, CEW, Sephora, Industry, EDO, Personal care, Intention, LVMH, VP, Marketing, Beauty, The Beauty Market, Brand activism, Dyson, CVS Health, Woman, Achievement, Program, Meta, Female, NARS Cosmetics, MMC, Leadership, Management, Parlux, Unilever, Enneagram of Personality, Nordstrom

NEW YORK, June 7, 2022 /PRNewswire/ -- Cosmetic Executive Women (CEW) celebrated women and achievement Friday at the 2022 Women's Leadership Awards – a program that embodies CEW's mission to motivate, elevate, and advance female leaders who are shaping the beauty industry today.

Key Points: 
  • NEW YORK, June 7, 2022 /PRNewswire/ -- Cosmetic Executive Women (CEW) celebrated women and achievement Friday at the 2022 Women's Leadership Awards a program that embodies CEW's mission to motivate, elevate, and advance female leaders who are shaping the beauty industry today.
  • "The Achiever Award recipients are the futureof the beauty business, representing different backgrounds, experiences, cultures, ages, leadership styles and points of view," said Carlotta Jacobson, CEW President.
  • They are expanding our industry in new directions, and building a better, more equitable workplace."
  • Event partners includeBeauty Inc, Fairchild Media Group, Consultancy Media, Kaplow Communications, Badger Agency, and Suite K.
    Cosmetic Executive Women (CEW) is an international organization of 9,000+ individual members representing beauty and related businesses, including leading brands, indies, retailers, media, and suppliers.

PepGen Announces Pricing of Initial Public Offering

Retrieved on: 
Friday, May 6, 2022
808, State Street, U.S. Securities and Exchange Commission, Telephone, GLOBE, LLC, Company, Peptide, Form, Attention, 3rd Floor, Montgomery Street, Security (finance), Prospectus, Therapy, BofA Securities, Sale, SEC, Research, Suite, EDO, Nasdaq, Incorporated, Stifel

The offering consists of 9,000,000 shares of common stock at an initial public offering price of $12.00 per share.

Key Points: 
  • The offering consists of 9,000,000 shares of common stock at an initial public offering price of $12.00 per share.
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by PepGen, are expected to be $108.0 million.
  • In addition, PepGen has granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
  • These risks and uncertainties include, but are not limited to market conditions and the satisfaction of customary closing conditions related to the initial public offering.

Xandr Enables Multiple TV Currencies for Data-Driven Linear Campaigns Heading Into Upfronts

Retrieved on: 
Thursday, April 21, 2022
Software, Audio, Video, TV and Radio, Advertising, Data Management, Communications, Technology, Entertainment, Advertising, AT&T, Adoption, T-Mobile US, VP, Research, AT, Learning, Â, EDO, SVP, Technology, GroupMe, Investment, Crown Media Holdings, Samba TV, Industry, Time, Comscore, Television, Marketing, Public relations, Xandr, Monetization

This capability will enable customers to seamlessly activate their preferred viewership or engagement data currency for data-driven linear campaigns using Xandrs buy and sell-side advanced TV platforms, Invest TV and Monetize TV.

Key Points: 
  • This capability will enable customers to seamlessly activate their preferred viewership or engagement data currency for data-driven linear campaigns using Xandrs buy and sell-side advanced TV platforms, Invest TV and Monetize TV.
  • This development is a direct result of the seismic shift from a single to multi-currency TV marketplace.
  • Xandr is making investments to power the adoption of new currencies and propel the industry forward.
  • Our data-enabled technology platform, encompassing Xandr Invest, Xandr Monetize and Xandr Curate, optimizes return on investment for both buyers and sellers.

KIA AMERICA WINS MULTIPLE MARKETING HONORS DURING 2022 NEW YORK INTERNATIONAL AUTO SHOW

Retrieved on: 
Friday, April 15, 2022
Advertising, Telluride, Marketing, EV6, Growth, EDO, Movement, Photography, Goliath, Sport utility vehicle, Carnival, Industry, Multimedia, NBA, Gasoline, Public relations, Video game, K5, Kia

In addition, marketing trade journal, MediaPost, named Kia's "Times Square Takeover" for the all-electric Kia EV6 "Best Interactive Execution or Campaign."

Key Points: 
  • In addition, marketing trade journal, MediaPost, named Kia's "Times Square Takeover" for the all-electric Kia EV6 "Best Interactive Execution or Campaign."
  • With assistance from agency partners including David&Goliath,Gail & Rice, Innocean, and Zeno Group, Kia took over the iconic New York City location for an in-person US debut of the EV6.
  • Headquartered in Irvine, California, Kia America continues to top automotive quality surveys and is recognized as one of the 100 Best Global Brands.
  • MediaPostis an integrated publishing and conference company whose mission is to provide a complete array of resources for media, marketing and advertising professionals.

Inaugural EDO Automotive TV Advertising Award Winners Announced at New York Auto Forum

Retrieved on: 
Tuesday, April 12, 2022
CEO, Advertising, Krim, K5, GLOBE, Oscar, EDO, Investment, Turbocharger, Convergence (TV program), Consumer, Motor vehicle, Public relations, Audi, Kia

NEW YORK, April 12, 2022 (GLOBE NEWSWIRE) -- Advertising data, measurement, and analytics software company EDO, Inc. announced today the winners of its inaugural Automotive TV Advertising Awards, presented at the New York Auto Forum .

Key Points: 
  • NEW YORK, April 12, 2022 (GLOBE NEWSWIRE) -- Advertising data, measurement, and analytics software company EDO, Inc. announced today the winners of its inaugural Automotive TV Advertising Awards, presented at the New York Auto Forum .
  • Winners were selected based on EDOs proprietary outcome measurement, which reflects brand-level consideration and intent as indicated by changes in consumer search generated by automotive brands TV ads.
  • "Were thrilled to partner with the New York Auto Forum to recognize the three automotive brands that produced the top-performing commercials of 2021," said Kevin Krim, President & CEO of EDO.
  • "All three winners each in their own way prove you dont have to choose between amazing brand-building creative and ads that directly drive demand and consumer response."

PepGen Announces First Participant Dosed in a Phase 1 Clinical Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

Retrieved on: 
Wednesday, April 6, 2022
EDO, LinkedIn, Safety, CTA, DM1, SAD, HNV, Clinical trial, Pharmacokinetics, Patient, Adult, Duchenne muscular dystrophy, Tolerability, Incidence, CEO, Lists of diseases, Technology, Oligonucleotide, Twitter, Dystrophin, Male, GLOBE, Genetic distance, Edos, Primate, Delivery, DMD, Health Canada, Pharmaceutical industry, Fine chemical

BOSTON, April 06, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced a critical clinical milestone for PGN-EDO51, the company’s lead product candidate for the treatment of Duchenne muscular dystrophy (DMD) patients whose mutations are amenable to an exon 51 skipping approach. Following the acceptance of PepGen’s Clinical Trial Application (CTA) by Health Canada last month, the company has now dosed the first healthy volunteer participant in a Phase 1 single ascending dose (SAD) clinical trial of PGN-EDO51.

Key Points: 
  • Following the acceptance of PepGens Clinical Trial Application (CTA) by Health Canada last month, the company has now dosed the first healthy volunteer participant in a Phase 1 single ascending dose (SAD) clinical trial of PGN-EDO51.
  • DMD is a devastating rare disease that places a significant burden on the lives of patients and their families.
  • The initiation of our Phase 1 HNV study is a significant milestone for PepGen and marks our transition to a clinical stage company.
  • The company is headquartered in Boston, Mass.For more information, visit www.pepgen.com or follow PepGen on Twitter and LinkedIn .

EDO Secures $80M Investment From Shamrock Capital

Retrieved on: 
Wednesday, April 6, 2022
Method, Family, LLP, The Walt Disney Company, Credit Suisse, Willkie Farr & Gallagher, CEO, Goldman Sachs, Kia, Technology, GLOBE, Amazon Studios, SoFi, Engineering, EDO, Patronage, Royal Caribbean, CBS, Marketing, The Carlyle Group, Convergence (TV program), Discovery, Industry, Warner Bros., Vista Equity Partners, TracFone Wireless, Investment, Shamrock Holdings, Data science, Board, Fox, Advertising, Ownership, Intelligence, NBCUniversal, Krim, Board of directors, TMT, Creativity, Partnership, S&P Global, Company, TaylorMade, IBM, Jim Breyer, Consumer, Convergent, Entertainment, Foundation, Machine learning, Shamrock, Cooley LLP, Hyundai, Univision, Video game, Public relations, Moat, Paramount, Nissan, Adweek, New Balance, Subway, Google, Nadler

In addition to Shamrocks strategic growth investment, EDO will expand its Board of Directors, which currently consists of Norton, Nadler, and legendary investor Jim Breyer, to include three new members: Shamrock Capital Partner Laura Held and Vice President Alicia Zhu, and EDO President & CEO Kevin Krim.

Key Points: 
  • In addition to Shamrocks strategic growth investment, EDO will expand its Board of Directors, which currently consists of Norton, Nadler, and legendary investor Jim Breyer, to include three new members: Shamrock Capital Partner Laura Held and Vice President Alicia Zhu, and EDO President & CEO Kevin Krim.
  • In her role at Shamrock, Zhu serves as a director of Skillable and has supported other Shamrock Capital investments including Ad Results Media and Pixellot.
  • Shamrock Capital is a Los Angeles-based investment firm with approximately $3.9 billion of assets under management.
  • Shamrock Capital partners with strong management teams and takes an active, collaborative approach to creating value in each investment.